Literature DB >> 27143006

Practising evidence-based medicine in an era of high placebo response: number needed to treat reconsidered.

Steven P Roose1, Bret R Rutherford2, Melanie M Wall2, Michael E Thase2.   

Abstract

The number needed to treat (NNT) statistic was developed to facilitate the practice of evidence-based medicine. Placebo was assumed to be therapeutically inert when the NNT was originally conceived, but more recent data for conditions such as major depressive disorder (MDD) suggest that the placebo control condition can have considerable therapeutic effects. Complications arise because the NNT calculated from randomised controlled trials (RCTs) reflects a comparison between medication plus clinical management and placebo plus clinical management, whereas, in the clinical setting, physicians choose between prescribing open medication, observing a patient over time with a supportive approach, and doing nothing. Thus, NNTs derived from clinical trials are not directly relevant to clinical decision-making, because they are based on control conditions that do not exist in standard practice. Additional difficulties may arise when using NNTs to compare alternative treatments for MDD, such as medication and psychotherapy, since these comparisons require the control conditions upon which the respective NNTs are based to be similar.Whereas pill placebo conditions include intensive clinical management and elicit expectations of improvement, attention control conditions for psychotherapy research are less well developed. Often the effects of psychotherapy are gauged against a wait-list control condition, which has substantially fewer therapeutic components than a pill placebo control condition. To improve the clinical utility of NNTs for the treatment of MDD, we advocate effectiveness studies that include treatment conditions resembling actual clinical practice, rather than using placebo-controlled RCTs for this purpose. Until such studies are performed, the effect of bias in comparing NNTs across treatments can be controlled by ensuring that the RCT control conditions upon which the NNTs are based are comparable. © The Royal College of Psychiatrists 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27143006      PMCID: PMC4853640          DOI: 10.1192/bjp.bp.115.163261

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  24 in total

1.  Measures of clinical significance.

Authors:  Helena Chmura Kraemer; George A Morgan; Nancy L Leech; Jeffrey A Gliner; Jerry J Vaske; Robert J Harmon
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-12       Impact factor: 8.829

Review 2.  Size of treatment effects and their importance to clinical research and practice.

Authors:  Helena Chmura Kraemer; David J Kupfer
Journal:  Biol Psychiatry       Date:  2005-12-20       Impact factor: 13.382

Review 3.  Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis.

Authors:  Michael A Posternak; Mark Zimmerman
Journal:  Br J Psychiatry       Date:  2007-04       Impact factor: 9.319

4.  An assessment of clinically useful measures of the consequences of treatment.

Authors:  A Laupacis; D L Sackett; R S Roberts
Journal:  N Engl J Med       Date:  1988-06-30       Impact factor: 91.245

5.  Frequency of follow-up care for adult and pediatric patients during initiation of antidepressant therapy.

Authors:  Glen D Stettin; Jianying Yao; Robert R Verbrugge; Robert E Aubert
Journal:  Am J Manag Care       Date:  2006-08       Impact factor: 2.229

6.  The functional neuroanatomy of the placebo effect.

Authors:  Helen S Mayberg; J Arturo Silva; Steven K Brannan; Janet L Tekell; Roderick K Mahurin; Scott McGinnis; Paul A Jerabek
Journal:  Am J Psychiatry       Date:  2002-05       Impact factor: 18.112

7.  The art of clinical management in pharmacologic trials with depressed elderly patients: lessons from the Pittsburgh Study of Maintenance Therapies in Late-Life Depression.

Authors:  M D Miller; E Frank; C F Reynolds
Journal:  Am J Geriatr Psychiatry       Date:  1999       Impact factor: 4.105

Review 8.  Placebo response in studies of major depression: variable, substantial, and growing.

Authors:  B Timothy Walsh; Stuart N Seidman; Robyn Sysko; Madelyn Gould
Journal:  JAMA       Date:  2002-04-10       Impact factor: 56.272

9.  Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs.

Authors:  Elaine H Morrato; Anne M Libby; Heather D Orton; Frank V Degruy; David A Brent; Richard Allen; Robert J Valuck
Journal:  Am J Psychiatry       Date:  2007-11-06       Impact factor: 18.112

10.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

Authors:  John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

View more
  6 in total

1.  Predicting Response to the Antidepressant Bupropion using Pretreatment fMRI.

Authors:  Kevin P Nguyen; Cherise Chin Fatt; Alex Treacher; Cooper Mellema; Madhukar H Trivedi; Albert Montillo
Journal:  Predict Intell Med (2019)       Date:  2019-10-10

Review 2.  Essential statistical principles of clinical trials of pain treatments.

Authors:  Robert H Dworkin; Scott R Evans; Omar Mbowe; Michael P McDermott
Journal:  Pain Rep       Date:  2020-12-18

Review 3.  Evidence-Based Psychotherapy: Advantages and Challenges.

Authors:  Sarah C Cook; Ann C Schwartz; Nadine J Kaslow
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

4.  Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial.

Authors:  Kevin P Nguyen; Cherise Chin Fatt; Alex Treacher; Cooper Mellema; Crystal Cooper; Manish K Jha; Benji Kurian; Maurizio Fava; Patrick J McGrath; Myrna Weissman; Mary L Phillips; Madhukar H Trivedi; Albert A Montillo
Journal:  Biol Psychiatry       Date:  2021-09-22       Impact factor: 13.382

Review 5.  Availability and use of number needed to treat (NNT) based decision aids for pharmaceutical interventions.

Authors:  Cassandra Nguyen; Mark Naunton; Jackson Thomas; Lyn Todd; John McEwen; Mary Bushell
Journal:  Explor Res Clin Soc Pharm       Date:  2021-06-24

6.  John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials.

Authors:  Shannon M Smith; Maurizio Fava; Mark P Jensen; Omar B Mbowe; Michael P McDermott; Dennis C Turk; Robert H Dworkin
Journal:  Pain       Date:  2020-09       Impact factor: 7.926

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.